A Phase 1b, Open-Label, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of MK-0482 As Monotherapy And In Combination With Pembrolizumab In Participants With Advanced/Metastatic Solid Tumors.